PBYI vs. AMGN: Which Stock Should Value Investors Buy Now?
https://www.zacks.com/stock/news/2224255/pbyi-vs-amgn-which-stock-should-value-investors-buy-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2224255
Feb 09, 2024 - PBYI vs. AMGN: Which Stock Is the Better Value Option?
0
Where Are Biotech ETFs Headed After Q4 Earnings?
https://www.zacks.com/stock/news/2226390/where-are-biotech-etfs-headed-after-q4-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2226390
Feb 14, 2024 - Look into how Biotech ETFs performed after Q4 earnings.
0
ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study
https://www.zacks.com/stock/news/2244204/acelyrin-slrn-up-on-data-from-thyroid-eye-disease-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244204
Mar 21, 2024 - ACELYRIN (SLRN) posts positive proof-of-concept data from a phase I/II study evaluating its pipeline candidate, lonigutamab, for treating thyroid eye disease. Stock gains.
0
Wall Street Awaits Consumer Confidence Data
https://www.zacks.com/stock/news/2246106/wall-street-awaits-consumer-confidence-data?cid=CS-ZC-FT-economic_highlights-2246106
Mar 26, 2024 - Wall Street Awaits Consumer Confidence Data
0
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
https://www.zacks.com/stock/news/2262673/astrazeneca-azn-q1-earnings-sales-beat-estimates-stock-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2262673
Apr 25, 2024 - AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.
0
What's in the Cards for Amgen (AMGN) This Earnings Season?
https://www.zacks.com/stock/news/2264395/what-s-in-the-cards-for-amgen-amgn-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-2264395
Apr 29, 2024 - Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
0
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
https://www.zacks.com/stock/news/2265330/will-these-5-drug-biotech-stocks-beat-q1-earnings-forecast?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2265330
Apr 30, 2024 - Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
0
Here's What Key Metrics Tell Us About Amgen (AMGN) Q1 Earnings
https://www.zacks.com/stock/news/2267471/here-s-what-key-metrics-tell-us-about-amgen-amgn-q1-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2267471
May 02, 2024 - The headline numbers for Amgen (AMGN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0
Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies
https://www.zacks.com/stock/news/2274187/eli-lilly-lly-settles-with-spa-selling-mounjaro-zepbound-copies?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2274187
May 15, 2024 - Eli Lilly (LLY) reaches settlement with a medical spa selling copycat versions of Mounjaro and Zepbound. The spa will make a monetary payment to Lilly.
0
Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data
https://www.zacks.com/stock/news/2274860/roche-rhhby-posts-encouraging-phase-i-obesity-drug-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2274860
May 16, 2024 - Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.
0